Phosphoenolpyruvate Restricts cGAS-Driven Inflammation in Aging

Study Background and Research Question

Aging is characterized by a gradual decline in physiological function, heightened disease susceptibility, and the emergence of chronic, low-grade inflammation—termed 'inflammaging'. This persistent inflammatory state is implicated in the pathogenesis of neurodegenerative, cardiovascular, and metabolic diseases. While the role of pro-inflammatory factors in aging is well documented, less is known about the existence and function of endogenous self-protective mechanisms that counteract inflammaging. Recent evidence has highlighted the centrality of the cyclic GMP-AMP synthase (cGAS)–STING signaling pathway in mediating age-associated inflammation, particularly in response to cytoplasmic DNA accumulation resulting from cellular senescence and mitochondrial dysfunction. However, the regulatory landscape governing cGAS–STING activity in the aged systemic milieu remains incompletely understood. This study addresses whether metabolic intermediates within the glycolytic pathway, specifically phosphoenolpyruvate (PEP), can serve as intrinsic modulators of cGAS-driven inflammation and thereby influence the trajectory of healthy aging.

Key Innovation from the Reference Study

The core innovation of the reference study (Song et al., 2026) lies in the identification of PEP as an endogenous inhibitor of the cGAS–STING inflammatory axis during aging. The researchers discovered that PEP levels in plasma and tissues follow a biphasic pattern: initial accumulation during middle age, followed by a progressive decline in later life. Crucially, this metabolite is shown to directly bind the cGAS enzyme, thereby restricting its activation and downstream pro-inflammatory signaling. The study demonstrates that preserving or supplementing PEP levels can mitigate age-related chronic inflammation, delay phenotypic markers of aging, and improve cognitive outcomes in mouse models of neurodegeneration.

Methods and Experimental Design Insights

The study employed a combination of longitudinal metabolomic profiling, genetic manipulation, biochemical assays, and animal models to dissect the role of PEP in aging:

• Longitudinal analyses of plasma and tissue metabolite levels were performed in both mice and humans, revealing age-dependent changes in PEP concentrations.
• Pharmacologic and genetic approaches were used to modulate PEP levels in vivo, including PEP supplementation and inhibition of glycolytic enzymes upstream of PEP synthesis.
• Plasma transfer experiments evaluated the impact of the aged systemic milieu on cGAS–STING activation in recipient mice.
• Direct binding assays (e.g., surface plasmon resonance) established that PEP competitively interacts with the cGAS protein, thereby blocking its activation by cytoplasmic DNA.
• Functional outcomes included inflammatory cytokine profiling, histopathological assessment, and behavioral tests in Alzheimer's disease (AD) mouse models.

This multifaceted approach enabled the researchers to link metabolic flux, enzymatic regulation of carbohydrate metabolism, and inflammatory signaling modulation within the context of aging biology.

Core Findings and Why They Matter

The study’s principal findings are as follows:

• Biphasic PEP trajectory: Both mice and human cohorts exhibited an initial rise in PEP levels during midlife, followed by a significant decline in advanced age. This pattern was conserved across tissues and plasma samples.
• Protective effect of PEP accumulation: High PEP levels correlated with reduced systemic inflammation and delayed onset of aging phenotypes. In contrast, experimental depletion of PEP accelerated inflammatory responses and functional decline.
• Mechanistic inhibition of cGAS–STING: PEP was shown to bind cGAS, acting as a competitive inhibitor and thus attenuating the production of type I interferons and pro-inflammatory cytokines that drive inflammaging.
• Intervention potential: Preemptive PEP supplementation in mice before the age-associated drop in endogenous PEP protected against neuroinflammation and cognitive impairment, particularly in an Alzheimer’s disease model.

These results support a paradigm in which glycolytic metabolites, beyond their canonical roles in energy production, function as key regulators of innate immune signaling and tissue homeostasis during aging. The data suggest that interventions targeting metabolic intermediates could form the basis for novel geroprotective strategies.

Comparison with Existing Internal Articles

The present study’s findings are reinforced by related research on glycolytic intermediates as modulators of inflammation and energy homeostasis. For example, Phosphoenolpyruvate as an Endogenous Inflammation Modulator in Aging further contextualizes PEP’s regulatory function within the cGAS–STING pathway, emphasizing its translational significance for neurodegenerative disease models. In parallel, Hexose Diphosphate in Energy Homeostasis and Inflammation Control highlights the broader class of hexose phosphates—including hexose diphosphate—as vital tools in energy homeostasis research and inflammatory signaling modulation. These internal resources collectively underscore the emerging view that metabolic flux probes, such as hexose diphosphate and PEP, are instrumental not only in dissecting carbohydrate metabolism but also in decoding the interface between metabolism and immune signaling. The workflow recommendations in Hexose Diphosphate: Applied Workflows for Metabolic Flux & Inflammation further illustrate how water-soluble hexose phosphates can be leveraged to interrogate both glycolytic dynamics and inflammatory mediator production in cardiovascular and aging research models.

Limitations and Transferability

While the reference study provides compelling evidence for the role of PEP in restricting inflammaging, several limitations warrant consideration. Firstly, the mechanistic insights are predominantly derived from murine models and in vitro assays; extrapolation to human aging and disease contexts, though supported by correlative data, will require direct clinical investigation. Second, the specificity of PEP’s interaction with cGAS versus other DNA sensors remains to be fully elucidated. Third, the translational utility of PEP supplementation is constrained by pharmacokinetic and tissue distribution challenges, as well as potential off-target metabolic effects. Additionally, the study does not address whether other hexose phosphates or glycolytic intermediates exert similar regulatory effects on cGAS–STING or related pathways. These limitations highlight the need for further research into the transferability and optimization of metabolic interventions for inflammaging.

Protocol Parameters

• PEP administration: Initiate supplementation before natural decline in endogenous levels (midlife in murine models); dosing and timing should be titrated based on plasma/tissue monitoring.
• Plasma transfer assays: Employ aged mouse or human plasma to evaluate systemic milieu effects on recipient immune activation.
• cGAS–STING pathway readouts: Use quantitative cytokine assays, interferon-stimulated gene expression, and histological scoring to assess inflammatory response.
• Comparative metabolic flux analysis: Incorporate hexose diphosphate or related metabolic probes to delineate glycolytic flux and regulatory node engagement in experimental models.

Why this cross-domain matters, maturity, and limitations

The connection between metabolic intermediates, such as PEP and hexose diphosphate, and immune regulation bridges the domains of cellular metabolism, inflammaging, and neurodegeneration. This cross-domain perspective is mature in preclinical models but requires further validation in human trials. The translational pipeline from metabolic pathway manipulation to clinical intervention remains an area of active investigation, particularly regarding the safety, efficacy, and durability of such interventions in complex aging phenotypes.

Research Support Resources

Researchers aiming to interrogate glycolytic flux, energy homeostasis, or inflammatory signaling in aging and disease models can utilize hexose diphosphate (SKU M1436) as a versatile metabolic probe. According to the product information, this water-soluble hexose phosphate is well-suited for cardiovascular ischemia models, metabolic flux assays, and studies of inflammation-related signaling. APExBIO supplies this compound in a form optimized for research applications, facilitating advanced investigations into the interplay between metabolism and immune modulation.